Want to join the conversation?
$ISRG's total pro forma instrument and accessory revenue grew to $298MM, up 10% year over year. Pro forma operating profit was $240MM in 3Q15. $ISRG submitted 510(k) for its Single-Site instrument chip for Xi, and a 510(k) application for its 30 millimeter stapler for Xi in 3Q15.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.